DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
51 hedge funds and large institutions have $17.8M invested in DMK Pharmaceuticals Corporation Common Stock in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 3 reducing their positions, and 12 closing their positions.
567% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 3
99% more call options, than puts
Call options by funds: $1.85M | Put options by funds: $930K
39% more capital invested
Capital invested by funds: $12.8M → $17.8M (+$5M)
4% less funds holding
Funds holding: 53 → 51 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.41M |
| 2 |
GC
Greenlight Capital
New York
|
+$870K |
| 3 |
BlackRock
New York
|
+$743K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$507K |
| 5 |
State Street
Boston,
Massachusetts
|
+$327K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$773K |
| 2 |
Millennium Management
New York
|
-$347K |
| 3 |
VF
Virtu Financial
New York
|
-$326K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$118K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$76.9K |
DMK Hedge Fund Activity: Q2 2021 in Review
51 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q2 2021, worth a combined $17.8M — up 39% from $12.8M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of DMK and 10 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 20 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $1.41M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $773K sold.
- 51 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q2 2021, down from 53 in Q1 2021.
- Funds reported $17.8M of DMK Pharmaceuticals Corporation Common Stock stock for Q2 2021, up 39% quarter-over-quarter.
- 10 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q2 2021 and 12 closed out, a net change of -2 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q2 2021 was Balyasny Asset Management, an estimated $1.41M added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q2 2021 was Renaissance Technologies, an estimated $773K sold.
Based on aggregated 13F filings for Q2 2021.